Preferred Name |
danazol |
|
Synonyms |
Danocrine |
|
Definitions |
A synthetic androgen derived from ethinyl testosterone. Danazol indirectly reduces estrogen production by decreasing pituitary secretion of follicle-stimulating hormone and luteinizing hormone, and binds to sex hormone receptors in target tissues, thereby exhibiting antiestrogenic, anabolic and weakly androgenic effects. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C414" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C414" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039204 |
|
altLabel |
Danocrine Bonzol 17alpha-ethynyl-17beta-hydroxy-4-androsteno[2,3-d]isoxazole Win-17757 DAN 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-cyclopental[7,8]phenanthro[3,2-d]isoxazol-1-ol Winobanin Danol Cyclomen (17alpha)-pregna-2,4-dien-20-yno[2,3-d]-isoxazol-17-ol Chronogyn Ladogal Danoval |
|
CAS Registry |
17230-88-5 |
|
Component of | ||
cui |
C5442089 C0733892 C0733889 C5442090 C5442088 C0813502 C0010961 C1511718 C1511717 C1527277 |
|
Date last modified |
2006-12-12 |
|
definition |
A synthetic androgen derived from ethinyl testosterone. Danazol indirectly reduces estrogen production by decreasing pituitary secretion of follicle-stimulating hormone and luteinizing hormone, and binds to sex hormone receptors in target tissues, thereby exhibiting antiestrogenic, anabolic and weakly androgenic effects. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C414" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C414" NCI Thesaurus) |
|
Legacy PDQ ID |
1827 |
|
LT |
TRD |
|
NCI ID |
C414 |
|
notation |
CDR0000039204 |
|
NSC Code |
270916 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
danazol |
|
tui |
T125 T109 T121 |